New ASCIA Radiocontrast Media Position Statement - July 2022
The new ASCIA Radiocontrast Media Position Statement for health professionals is available at https://www.allergy.org.au/hp/drug-allergy/radiocontrast-media
Radiocontrast media (RCM) are a group of medical drugs used to improve the visibility of internal organs and structures of X-ray based imaging, such as plain film radiography and computed tomography (CT) scans. Adverse events related to administration of RCM include hypersensitivity (allergic-type) reactions and radiocontrast-induced nephropathy.
This statement focuses on hypersensitivity reactions to intravenous administered iodinated RCM.
It is important that all nurses, radiographers and medical practitioners who administer RCM are trained in the recognition of contrast reactions, the procedures for treating these reactions (including anaphylaxis), and resuscitation procedures (including CPR).
Although anaphylaxis to RCM is uncommon, it is important that any service using RCM is equipped and trained to treat anaphylaxis, which has been highlighted by a report from the Coroners Court of Victoria regarding the death of Peta Hickey on 9 May 2019. coronerscourt.vic.gov.au/sites/default/files/2021-12/HickeyPeta_233619.pdf
This news item was issued on 31 July 2022 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.